All coronary artery bypass graft surgery patients will benefit from angiotensin-converting enzyme inhibitors.

@article{Lazar2008AllCA,
  title={All coronary artery bypass graft surgery patients will benefit from angiotensin-converting enzyme inhibitors.},
  author={Harold L. Lazar},
  journal={Circulation},
  year={2008},
  volume={117 1},
  pages={6-8}
}
Angiotensin-converting enzyme (ACE) inhibitors have been shown to prolong survival and to decrease infarct size in patients after acute coronary syndromes.1–3 Evidence now exists that ACE inhibitors are effective in decreasing myocardial injury during coronary artery bypass graft surgery (CABG) and can reduce the incidence of ischemic events in the years after surgery.4,5 It has been suggested that all CABG patients be started on ACE inhibitors, in addition to a statin, aspirin, and -blocker… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Quinapril with high affinity to tissue angiotensin-converting enzyme inhibitor reduces reste nosis after percutaneous transcatheter coronary revascularization

  • T Okimoto, M Imazu, Y Hayaghi, Y. Yamaguchi
  • J Am Coll Cardiol. 2000;35:37A. Abstract
  • 2000

Differential action of angiotensin II and activity of angiotensinconverting enzyme in human bypass grafts

  • JAA Borlan, AH Chester, S Crabbe, JB Parkerson, JD Catravas, MH. Yacoub
  • J Thorac Cardiovasc Surg
  • 1998

Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension

  • NJ Brown, MA Agirbasli, GH William, WR Litchfield, DE. Vaughan
  • 1998

Similar Papers

Loading similar papers…